| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_a933a0dd561e3e50b278738704d5c6e6
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_b05d5871638d5180bb954591361c7635 |
| classificationCPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K2039-57
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K39-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N2740-16222
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N2740-16122 |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P31-18
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K14-005 |
| classificationIPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K39-00 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P31-18
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K14-16
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12Q1-02
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K7-06
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K39-21 |
| filingDate |
2002-03-01-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_51103bc638cf489853eddee8ffe6d0c4
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_e83d7bd0f3826d9393bfe0ef4e791bfa
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_5557f740d0c6d6abb9df569806e652b9
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_dbf0f95d0b7f7973b85aa1303cc1c7fb
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_0bb07fb2fc544066bc2ec62ab95fbc15 |
| publicationDate |
2004-12-29-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
EP-1490396-A2 |
| titleOfInvention |
Immunogenic hiv peptides for use as reagents and vaccines |
| abstract |
Immunogenic HIV peptides and methods of use are provided in which each HIV peptide include epitopes that are immunoreactive with cytotoxic T lymphocytes (CTLs) from HIV-positive individuals and binds to antibodies that are immunoreactive with the assembled class I major histocompatibility complex (MHC) structure. Preferably, the peptide is an isolated or synthetic peptide containing between nine and eleven amino acid residues within specific regions of the HIV genome. |
| priorityDate |
2001-03-01-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |